Tumor marker response to <scp>SARS‐CoV</scp>‐2 infection among patients with cancer

Gunn, Alexander; Tashie, Carolyn; Wolf, Steven; Troy, Jesse D.; Zafar, Yousuf

doi:10.1002/cam4.4646

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported, smoking can increase the expression of angiotensin-converting enzyme 2 (ACE2) in lung tissues, which is one of the binding receptors of SARS-CoV-2 ( Ponti et al., 2020 ). Additionally, old age, which is accountable for reduced effectiveness in the immune system, is partially responsible for the increased prevalence and severity of infectious diseases ( Gunn et al., 2022 ). This could explain why the male, elderly patients and those with any comorbidities, especially with hypertension and diabetes, were more likely to develop into severe cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19

Yang,

Liu,

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic is a rapidly evolving global emergency and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. In order to early identify severe and critical patients, we retrospectively analyze the clinical characteristics and risk indicators of severe disease in patients with corona virus disease 2019 (COVID-19).MethodsA total of 420 confirmed COVID-19 patients were included in the study. According to the “Diagnosis and Treatment of novel coronavirus Pneumonia (10th Edition)”, the cases were divided into mild group (n = 243) and severe group (n =177). Laboratory parameters were analyzed in combination with clinical data.ResultsMale patients over 46 years who have smoking habits were more likely to suffer from severe COVID-19. Critically ill patients had lower lymphocyte counts and red blood cell counts, and higher white blood cell counts (P<0.05). Expectedly, serum inflammatory factors (NLR, PLR, LMR, CLR, PCT, CRP), coagulation markers (APTT, PT, TT, FIB, D-Dimer), Myocardial damage markers (hs-TNT, LDH) were significantly increased (P<0.05) in severe COVID-19 patients. Surprisedly, those patients showed obviously elevated levels of common tumor markers (ProGRP, CYFRA21-1, SCC, NSE) (P<0.05). In this case, the levels of tumor marker reflected more the condition of inflammation than the growth of tumor. More importantly, HA and PIIIN-P were highly associated with COVID-19 severity. The AUC of the ROC curve for the diagnosis of severe COVID-19 by HA and PIIIN-P was 0.826. Meanwhile, HA was positively correlated with myocardial damage markers (hs-TNT, LDH). PIIIN-P was positively correlated with myocardial damage markers (hs-TNT, LDH) and inflammatory factors (NLR, PLR, LMR, CLR, ProGRP, SCC, PCT, CRP). On the contrary, PIIIN-P was negatively correlated with pulmonary function indexes (oxygenation index and oxygen saturation of hemoglobin).ConclusionHA and PIIIN-P are highly associated with disease severity and progression of COVID-19 and can be used as new markers for the prediction of severe COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Given patients with previous or current history of cancer were excluded in this study, ProGRP, CYFRA21-1, SCC reflected more the condition of inflammation than the tumor risk. It is believed that inflammatory responses from benign conditions can cause non-cancer-related elevations in tumor markers ( Gunn et al., 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19

Yang,

Liu,

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…If the amount of CA125 does not change or rises following treatment, it could indicate that the cancer is not responding. After treatment, an increased CA125 result could indicate that cancer has returned [ 97 , 101 ]. One of the factors that affect the CA125 concentration is fluid effusion and retention.…”

Section: Muc16 (Ca 125) and Non-malignant Proliferationmentioning

confidence: 99%

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity

et al. 2022

View full text Add to dashboard Cite

Lung cancer is the second most commonly diagnosed cancer in the world. In terms of the diagnosis of lung cancer, combination carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125) detection had higher sensitivity, specificity, and diagnostic odds ratios than CEA detection alone. Most individuals with elevated serum CA125 levels had lung cancer that was either in stage 3 or stage 4. Serum CA125 levels were similarly elevated in lung cancer patients who also had pleural effusions or ascites. Furthermore, there is strong evidence that human lung cancer produces CA125 in vitro, which suggests that other clinical illnesses outside of ovarian cancer could also be responsible for the rise of CA125. MUC16 (CA125) is a natural killer cell inhibitor. As a screening test for lung and ovarian cancer diagnosis and prognosis in the early stages, CA125 has been widely used as a marker in three different clinical settings. MUC16 mRNA levels in lung cancer are increased regardless of gender. As well, increased expression of mutated MUC16 enhances lung cancer cells proliferation and growth. Additionally, the CA125 serum level is thought to be a key indicator for lung cancer metastasis to the liver. Further, CA125 could be a useful biomarker in other cancer types diagnoses like ovarian, breast, and pancreatic cancers. One of the important limitations of CA125 as a first step in such a screening technique is that up to 20% of ovarian tumors lack antigen expression. Each of the 10 possible serum markers was expressed in 29–100% of ovarian tumors with minimal or no CA125 expression. Therefore, there is a controversy regarding CA125 in the diagnosis and prognosis of lung cancer and other cancer types. In this state, preclinical and clinical studies are warranted to elucidate the clinical benefit of CA125 in the diagnosis and prognosis of lung cancer.

show abstract

“…A case report of a patient being treated for ovarian cancer noted a transient elevation in CA-125 following SARS-CoV-2 infection without evidence of cancer progression on standard imaging, raising the possibility that SARS-CoV-2 infection may increase CA-125 independent of cancer recurrence or progression ( Smith et al, 2020 ). Another recent report of a patient with ovarian cancer showed a temporary increase in CA-125 following a mild SARS-CoV-2 infection, however it is unknown whether she had simultaneous disease progression ( Gunn et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?

Thayer¹,

Walsh²,

Leung³

et al. 2023

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Tumor marker response to SARS‐CoV‐2 infection among patients with cancer

Cited by 4 publications

References 34 publications

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity

Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?

Contact Info

Product

Resources

About